XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment

Key Takeaways

• PEP08, a next-generation PRMT5 inhibitor discovered using XtalPi’s AI platform, has successfully begun Phase I solid tumor trial enrollment
• The partnership between XtalPi and PharmaEngine has launched a second synthetic lethality program building on PEP08’s success
• This milestone demonstrates the potential of AI-powered drug discovery in advancing cancer treatments targeting synthetic lethal pathways

---

SHENZHEN, China - XtalPi (2228.HK), a leading AI and robotics-powered drug discovery platform, announced that PEP08, a PRMT5 inhibitor developed through its partnership with PharmaEngine (4162.TWO), has achieved a critical milestone by beginning patient enrollment in Phase I clinical trials for solid tumors.

AI-Powered Drug Discovery Success

PEP08 represents a breakthrough in synthetic lethality cancer treatment, targeting PRMT5 (protein arginine methyltransferase 5), an enzyme crucial for cancer cell survival. The drug was discovered using XtalPi’s proprietary AI and robotics platform, which accelerates the identification and optimization of therapeutic compounds.

Synthetic lethality is an emerging cancer treatment approach that exploits genetic vulnerabilities in tumor cells. When cancer cells lose one essential gene function, targeting a second related pathway becomes lethal to the cancer while sparing healthy cells.

Expanding Partnership Pipeline

Building on PEP08’s clinical advancement, XtalPi and PharmaEngine have initiated a second collaborative project focusing on synthetic lethality mechanisms. This expansion demonstrates the companies’ confidence in their AI-driven drug discovery approach and the potential for developing multiple cancer therapies.

The Phase I trial will evaluate PEP08’s safety, tolerability, and preliminary efficacy in patients with solid tumors. PRMT5 inhibitors have shown promise in preclinical studies for treating various cancer types, particularly those with specific genetic mutations that make them vulnerable to PRMT5 targeting.

Market Impact and Future Outlook

This milestone positions both companies at the forefront of AI-powered oncology drug development. The successful transition from discovery to clinical testing validates XtalPi’s platform capabilities and could accelerate similar partnerships in the pharmaceutical industry.

The global PRMT5 inhibitor market is expected to grow significantly as more companies recognize the therapeutic potential of targeting this enzyme in cancer treatment. PEP08’s progression to human trials represents a significant step toward potentially bringing new treatment options to cancer patients.

---

Frequently Asked Questions

What does this mean for cancer patients?

PEP08 entering Phase I trials means a new potential treatment option is being tested for safety and effectiveness in solid tumor patients, though it will take several years of clinical testing before potential approval.

When will PEP08 be available to patients?

PEP08 is currently in Phase I trials, which typically take 1-2 years. If successful, it would need to complete Phase II and III trials, meaning potential availability is likely 5-8 years away, pending regulatory approval.

How does PEP08 compare to existing cancer treatments?

PEP08 uses a synthetic lethality approach targeting PRMT5, which is designed to selectively kill cancer cells while sparing healthy tissue, potentially offering fewer side effects than traditional chemotherapy.